The Aesthetic Guide is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

New injectable fillers may soon be competing in the U.S. market

Article-New injectable fillers may soon be competing in the U.S. market

Boston — Restylane (Medicis), an injectable filler used to smooth lines and wrinkles, may face a market challenge from another filler brand in keeping its second-place status to the substantially more widely used injectable, Botox (Allergan).

According to investment Boston-based banking firm Leerink Swann, Restylane could get strong competition from Juvederm, which will be placed on the market by Inamed if the filler wins approval from the Food and Drug Administration.

Medicis officials say they’re not concerned about the potential new U.S. competition because despite the fact that Restylane is more expensive than Juvederm, Restylane already has competed successfully within Europe and Canada.

Cathay Financial, a financial services firm based in Taiwan, reports that Mentor Corp. also is developing yet another Restylane competitor called Puragen, which Cathay Financial says will be submitted for FDA approval in March.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.